Article Details
Retrieved on: 2021-08-05 20:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca has offloaded its BRD4 BET inhibitor AZD5153 to Sierra Oncology. Sierra plans to start a phase 2 trial testing the drug in combination ...
Article found on: www.fiercebiotech.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here